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Abstract
Background
There are few real-life data on the potential drug-drug interactions (DDIs) between anti-HCV
direct-acting antivirals (DAAs) and the comedications used.
Aim
To assess the potential DDIs of DAAs in HCV-infected outpatients, according to the severity
of liver disease and comedication used in a prospective multicentric study.
Methods
Data from patients in 15 clinical centers who had started a DAA regimen and were receiving
comedications during March 2015 to March 2016 were prospectively evaluated. The DDIs
for each regimen and comedication were assigned according to HepC Drug Interactions
(www.hep-druginteractions.org).
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Results
Of the 449 patients evaluated, 86 had mild liver disease and 363 had moderate-to-severe
disease. The use of a single comedication was more frequent among patients with mild liver
disease (p = 0.03), whereas utilization of more than three drugs among those with moder-
ate-to-severe disease (p = 0.05). Of the 142 comedications used in 86 patients with mild dis-
ease, 27 (20%) may require dose adjustment/closer monitoring, none was contraindicated.
Of the 322 comedications used in 363 patients with moderate-to-severe liver disease, 82
(25%) were classified with potential DDIs that required only monitoring and dose adjust-
ments; 10 (3%) were contraindicated in severe liver disease. In patients with mild liver dis-
ease 30% (26/86) used at least one drug with a potential DDI whereas of the 363 patients
with moderate-to-severe liver disease, 161 (44%) were at risk for one or more DDI.
Conclusions
Based on these results, we can estimate that 30–44% of patients undergoing DAA and tak-
ing comedications are at risk of a clinically significant DDI. This data indicates the need for
increased awareness of potential DDI during DAA therapy, especially in patients with mod-
erate-to-severe liver disease. For several drugs, the recommendation related to the DDI
changes from “dose adjustment/closer monitoring”, in mild to moderate liver disease, to “the
use is contraindicated” in severe liver disease.
Introduction
The new generation of oral direct-acting antivirals (DAAs) has transformed the treatment of
hepatitis C virus (HCV) infection, demonstrating both high efficacy and high tolerability [1–
3]. However, none of the DAAs are completely free of drug-drug interactions (DDIs), which
can significantly alter the drugs’ exposure and thus their efficacy and toxicity. Studies on inter-
actions between DAAs and some key drugs have been performed in the development of all
DAAs. However, the majority of clinical trial participants have been healthy volunteers with
few comorbidities and limited concomitant medications [4,5].
Clinical implications of established or potential DDIs between DAAs and comedications
vary, as do the effects of hepatic and renal impairment on DAAs and other drugs. Interactions
may lead to decreased concentrations resulting in decreased efficacy (i.e lack of therapeutic
effect) or increased peak concentrations associated with increased drug toxicity.
In patients with severe liver disease, determining the effect of DDIs between DAAs and
comedications remains a challenge. This challenge is further complicated by ageing and addi-
tional comorbidities in chronic HCV patients, often resulting in polypharmacy.
There is limited data available that addresses DDIs in patients with chronic HCV infection
[6]. The objective of the present study was to assess the potential DDIs of DAAs with medica-
tions used in outpatients that began anti-HCV Interferon (IFN)-free therapy as part of the
PITER Cohort Study (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) [7].
Patients and methods
Patients
For the present prospective multicentric real life study, we evaluated data from patients who
were initiated a DAA IFN-free regimen in the period from March 2015 to March 2016 and
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who were receiving at least one comedication. The data were provided by those 15 clinical cen-
ters involved in the PITER Cohort Study that had available data on comedication during DAA
therapy. PITER is a collaboration involving Italy’s National Institute of Public Health (Istituto
Superiore di Sanità), the Italian Society for the Study of the Liver (AISF), and the Italian Soci-
ety for Infectious Diseases (SIMIT) [7]. The data were collected prospectively from the pre-
scribing clinician when the regimen was started, on the electronic case-report form used for
PITER. The DAAs available during the time period of this study which were evaluated in the
present work are reported in Table 1.
We evaluated DDIs according to the severity of liver disease and the specific comedications
used. The fibrosis stage was defined based on liver transient elastometry data, which were con-
sidered validated if each patient had at least 10 valid stiffness measurements, with a success
rate of at least 80%, an interquartile range of less than 30% of the median stiffness score, and a
Body Mass Index (BMI) of<30kg/m2. The severity of liver disease was classified as “mild” if
the stiffness score was equal to or lower than 10 kPa and as “moderate-to-severe” if it was
higher or if there were signs of liver cirrhosis (signs of portal hypertension) [8]. Patients coin-
fected with HIV or HBV and those included in clinical trials were excluded.
Assessment of comedications
Potential DDIs were assessed and classified based on information available at www.hep-
druginteractions.org. For most interactions, the information was based on the metabolism
pathway of each drug used, in the absence of clinical data. Specifically, the DDIs for each DAA
regimen and each drug used as comedication were assigned to four different risk categories:
Table 1. Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients
undergoing DAA therapy.
Patient Characteristics Severity of Liver Disease p-value
Mild N. Patients: 86 (%) Moderate-to-Severe N. Patients: 363 (%)
Median age 64 years (range: 29–82) 65 years (range: 45–82) 0.7
Gender: male/female 38/48 (44/54) 217/145 (60/40) <0.01
Genotype Distribution
1a 9 (11) 48 (13) 0.6
1b 46 (53) 186 (51) 0.7
2 17 (20) 52 (14) 0.2
3 7 (8) 55 (15) 0.1
4 7 (8) 22 (6) 0.5
Comedications
1 drug 34 (40) 100 (28) 0.03
2 drugs 18 (21) 81 (22) 0.9
3 drugs 15 (17) 65 (18) 1
4 drugs 10 (12) 55 (15) 0.4
5 drugs 5 (6) 32 (9) 0.5
>5 drugs (range 6–12) 4 (5) 33 (9) 0.2
DAA regimens
Sofosbuvir+Ribavirin 28 (33) 105 (29) 0.5
Sofosbuvir+Simeprevir 20 (23) 95 (26) 0.7
Sofosbuvir+Daclatasvir 6 (7) 40 (11) 0.3
Sofosbuvir+Ledipasvir 9 (10) 44 (12) 0.8
Paritaprevir/ritonavir, ombitasvir, dasabuvir 23 (27) 78 (21) 0.3
doi:10.1371/journal.pone.0172159.t001
Real-life data on potential DDI during DAA therapy
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Category 0: Classification not possible due to lack of information
Category 1: No clinical interaction possible
Category 2: May require dose adjustment/closer monitoring
Category 3: Co-administration not recommended or contraindicated
Each DDI was evaluated considering the stage of liver disease of each patient. Safety con-
cerns for a comedication due to hepatic impairment and not only due to an interaction with
the DAA were also considered in this study. Specifically, some DDIs were considered as Cate-
gory 2 or Category 3 only in patients with moderate-to-severe liver disease, whereas they were
considered as Category 1 in patients with mild liver disease.
Statistical analysis
Differences among the proportions were evaluated by chi-square or Fisher test, as appropriate.
A p-value of less than 0.05 was considered as significant.
Ethics
The protocol of PITER was approved by the Ethics Committee of ISS on 19th June 2013, and
by the Ethics Committees of each participating institution that are listed in the PITER Collabo-
rating Group available at www.iss.it/piter. All patients included in the database signed an
informed consent prior to enrolment. The patients’ data were evaluated through an anony-
mous analysis, adopting codes generated by the electronic case-report form.
Results
Characteristics of the study population and medications used
Of 147 patients who had mild disease (median stiffness: 8.1kPa; range: 4.1–9.9) and of 550
patients who had moderate-to-severe liver fibrosis and/or cirrhosis (median stiffness: 20.8;
range: 10.5–68.1; or clinical signs of liver cirrhosis), 86 (58%) and 363 (66%) patients respec-
tively were receiving comedications respectively. The characteristics of the patients and infor-
mation on comedications, by severity of liver disease at the time of starting DDA treatment,
are reported in Table 1.
The use of a single comedication was more frequent among patients with mild liver disease
(p = 0.03), whereas the use of more than three drugs was reported in 19 (22%) and 120 (33%)
patients with mild and moderate-to-severe liver disease respectively (p = 0.05). The most fre-
quently reported DAA regimens were sofosbuvir plus ribavirin (SOF/RBV), followed by pari-
taprevir/ritonavir, ombitasvir, dasabuvir (referred to as 3D) and sofosbuvir plus simeprevir
(SOF/SIM). The least common used regimens were sofosbuvir plus ledipasvir (SOF/LDV) and
sofosbuvir plus daclatasvir (SOF/DCV). There were no significant differences in use between
patients with mild compared to those with moderate to severe liver disease. In patients with
moderate-to-severe disease, the 3D regimen was used only in patients with Child-Pugh A
cirrhosis.
The drug classes of the comedications are reported in Table 2. Proton pump inhibitors,
diuretics and beta blockers were more frequently used in patients with moderate-to-severe
liver disease, whereas anxiolytic drugs were more common in patients with mild liver disease.
Similar frequencies were reported for other drug classes. Antipsychotic/antidepressives drugs
used in both populations are mainly selective serotonin reuptake inhibitor of which only ser-
traline is reported with possible DDIs.
Real-life data on potential DDI during DAA therapy
PLOS ONE | DOI:10.1371/journal.pone.0172159 February 28, 2017 4 / 11
The number of comedications, by DAA regimen, is reported in Fig 1A for patients with
mild disease and in Fig 1B for patients with moderate-to-severe disease.
Comedications with potential DDIs
The classification of DDIs, by severity of liver disease, is reported in Fig 2.
In both groups of patients, the greatest percentage of DAAs regimens with potential DDIs
was reported for the 3D regimen (45% of drugs used in patients with mild liver disease and
38% of drugs used in those with moderate-to-severe liver disease). In (80%) (12/15) of drugs
used in patients with mild liver disease and 54% (14/ 26) of those used in patients with moder-
ate-to-severe liver disease in combination with the 3D regimen, a DDI was reported between
ritonavir component of the 3D regimen and each drug used as comedication.
Overall, of the 142 comedications prescribed in patients with mild liver disease, 27 (20%)
were classified as Category 2 (“May require dose adjustment/closer monitoring”).
Overall, of the 322 comedications used in patients with moderate-to-severe liver disease, 82
drugs (25%) were classified as Category 2; of these, 10 (3%) were classified as Category 3 in
cases of their use in severe liver disease. All patients in whom these drugs were co administered
were in the Child-Pugh A liver cirrhosis stage.
The drugs most commonly reported as having at least one DDI in patients with moderate-
to-severe liver disease are shown in Table 3.
Use of comedications with potential DDIs in the study population
Of the 86 patients with mild liver disease, 26 (30%) used at least one drug with a potential DDI
(Category 2). Of these 26 patients, 11 (42%) were treated with the 3D regimen, the remaining
15 patients were equally distributed among the other regimens.
None of patients with mild liver disease used a contraindicated drug (Category 3) as
comedication.
Of the 363 patients with moderate-to-severe liver disease, 161 (44%) had more than one
DDI. Potential DDIs were more frequently found for the 3D regimen (n = 48 patients, 36%),
Table 2. Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.
Drug Class* Severity of Liver Disease p-value
Mild Moderate-to-Severe
N. Patients: 86 (%) N. Patients: 363 (%)
Ace Inhibitors 11 (13) 65 (18) 0.2
Antipsychotic/Antidepressives 12 (14) 40 (11) 0.4
Antiaggregant/Anticoagulant 15 (17) 48 (13) 0.3
Antibacterials/antiprotozoal 7 (8) 19 (5) 0.3
Antidiabetics 15 (17) 71 (20) 0.6
Anxyolitic/Hypnotic/Sedatives/ 19 (22) 43 (12) 0.01
Beta blockers 17 (20) 126 (35) <0.01
Ca antagonists 9 (11) 27 (7) 0.3
Diuretic (component of antihypertensive therapy) 15 (18) 155 (43) <0.001
Gastrointestinal other than PPI 10 (12) 60 (17) 0.2
PPI 16 (19) 124 (34) <0.01
Sartanic 15 (17) 52 (14) 0.4
Substitute Hormonal therapy 11 (13) 30 (8) 0.2
*Reported drug classes used in more than 5% of each group.
doi:10.1371/journal.pone.0172159.t002
Real-life data on potential DDI during DAA therapy
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Fig 1. Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.
(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin,
SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D:
paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three
drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each
regimen in both Fig 1A and Fig 1B at the same manner.
doi:10.1371/journal.pone.0172159.g001
Real-life data on potential DDI during DAA therapy
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followed by SOF/SIM (n = 40 patients, 25%).Similar prevalence rates of patients at risk for at
least one DDI were observed for the remaining sofosbuvir-based regimens (data not shown).
The 10 drugs reported to be contraindicated in severe liver disease were used by 63 (17%)
patients in with similar prevalence for all of the DAA regimens. No important clinical out-
comes were reported for these patients during the study period. However, this study is pro-
spective in design and the evaluation of important clinical outcomes and of the potential DDIs
is ongoing.
Fig 2. Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected
patients. Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver
disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin,
SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir,
3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information;
Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.
doi:10.1371/journal.pone.0172159.g002
Real-life data on potential DDI during DAA therapy
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Discussion
Polypharmacy has become an important issue among patients with HCV mono-infection, and
DDIs are one of the challenges in the DAA-based treatment of these patients [9,10]. The most
frequently reported drug interactions modify drug metabolism by inducing or inhibiting the
cytochrome P450, leading to abnormal drug exposure [10].
Many of the DDI studies have been performed in healthy volunteers, yet HCV-infected
patients with cirrhosis may have impaired CYP450 capacity and higher plasma concentrations
of CYP450 substrates compared to healthy individuals. This would mean that they are at even
more risk for drug toxicity when a DDI occurs. In light of this, different profiles of potential
drug-drug interactions have been hypothesized in patients with moderate-to-severe liver dis-
ease, however, few data are available for real-life patients [11–13].
Our real-life data stress that potential DDIs are an important clinical issue for individuals
treated with DAAs for chronic HCV infection. We found that a wide variety of drugs belong-
ing to different classes were used, even wider than that reported by Siederdissen et al. [6], who
conducted a single center survey and whose patients were around 10 years younger, presum-
ably with fewer comorbidities than those in our cohort.
Table 3. The most common drugs with a potential DDI among HCV-infected patients with moderate-
to-severe liver disease.
Drug N. Patients (%) DAA Regiments with Possible Category 2 DDIs
PPI 124 (34.2) SOF/LDV; 3D
Propranolol 70 (19.5) 3D
Furosemide 56 (15.4) 3D
Levothyroxin 30 (8.2) SOF/DCV; 3D
Lactulose 26 (7.1) 3D
UDCA 26 (7.1) SOF; SOF/SIM; SOF/DCV; SOF/LDV
Amlodipin 24 (6.6) SOF/SIM; SOF/DCV; SOF/LDV; 3D
Carvedilol*§ 18 (5) SOF; SOF/SIM; SOF/DCV; SOF/LDV; 3D
Rifaximin 18 (4.9) 3D
Irbesartan 15 (4.1) SOF/LDV; 3D
Prednisone 14 (3.8) SOF/SIM; 3D
Alpraxolam 12 (3.3) 3D
Olmesartan*§ 12 (3.3) SOF; SOF/SIM; SOF/LDV; 3D
Bisoprolol 11 (3) SOF; SOF/SIM; SOF/LDV; 3D
Sertralin§ 8 (2.2) SOF; SOF/SIM; SOF/DCV; 3D
Telmisartan 8 (2.2) 3D
Allopurinolo 7 (1.9) SOF; SOF/SIM; SOF/DCV; SOF/LDV
Doxazosin§ 7 (1.9) SOF; SOF/SIM; SOF/LDV; 3D
Enalapril 7 (1.9) 3D
Valsartan 7 (1.9) SOF; SOF/SIM; SOF/DCV; 3D
Nebivolol§ 6 (1.6) SOF/SIM; SOF/DCV; SOF/LDV
Propafenone 6 (1.7) SOF/SIM; SOF/LDV; 3D
Candesartan§ 5 (1.1) SOF; SOF/LDV; 3D
Lisinopril 5 (1.1) SOF/SIM; SOF/LDV
Lormetazepam 5 (1.1) 3D
*Dose adjustment only in the European Summary Product Characteristics. No dosage restrictions in the US
prescribing Information.
§ Contraindicated in patients with severe hepatic impairment.
doi:10.1371/journal.pone.0172159.t003
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The profile of the patients in our study mirrored the epidemiology of HCV infection in
Italy, whose prevalence is greatest among the elderly [14]. As a consequence, in our cohort,
polypharmacy was relatively common in patients with mild liver disease as in those with mod-
erate-to-severe liver disease. Of the patients with mild liver disease, 30% reported a potential
Category 2 DDI, for which the most suitable approach is monitoring for the early detection of
adverse events [6,15]. These data indicate that in patients with mild liver disease, through care-
ful pre-treatment assessment of concomitant medications and monitoring or dose-modifica-
tions, significant DDIs can be avoided even in elderly patients who generally take multiple
comedications for different comorbidities [10,16–19]. However, the use of contraindicated
comedications (Category 3 of DDI) should always be checked and, if present, an alternative
comedication should be provided, regardless of the severity of liver impairment. Our data
showed that none of the patients with mild liver disease were taking contraindicated comedi-
cations during DAA treatment, whereas 10% of the comedications were contraindicated in
patients with moderate-to-severe liver disease. Patients with moderate-to-severe liver disease
were a group of particular interest, due to the intersection between older age, comorbidities
and severity of liver disease. In this study, 44% of patients with severe liver disease were af-
fected by more than one DDI. Of these patients, 17% used comedications that are contraindi-
cated in cases of severe liver damage, mainly because of the possible deterioration of liver
disease. That these drugs were prescribed and the lack of important clinical outcomes during
ongoing DAA therapy could be explained by the fact that all were classified with Child-Pugh A
liver cirrhosis, which indicated that the liver impairment was not very severe. However, clini-
cians should be aware of the possible interactions reported for different comedications and
DAAs, in particular in patients with severe liver impairment [20].
Our series showed that DAA regimens containing a protease inhibitor (3D combination
with ritonavir or SOF/SIM) was associated with a higher risk for DDIs (38% and 32%, respec-
tively), compared to other SOF-containing regimens (11–23%). Furthermore, these regimens
were contraindicated in patients with advanced/decompensated liver cirrhosis. The mecha-
nism of DDIs in patients receiving the 3D regimen can primarily be attributed to the ritonavir
component of 3D, whose mechanism of action is to modify the metabolism of concomitant
drugs, mainly increasing concomitant drug concentrations [16].
Warnings on the administration of comedications with the DAA regimens that include
protease inhibitors (3D and Simeprevir regimens) were released in 2015, when our data were
being collected, which, over time, may have increased the awareness of possible DDIs related
to these regimens [15,21,22].
In general, regimens with the NS5B inhibitor sofosbuvir plus an HCV NS5A inhibitor (i.e.,
ledipasvir, daclatasvir), which do not affect CYP450, were relatively free of significant pharma-
cokinetic interactions, even in patients with moderate to severe liver impairment.
PPIs were the most frequently used comedication in our study (used in 19% and 34% of
patients with mild and moderate-to-severe liver disease, respectively). The possible DDIs
between PPIs and DAAs has been emphasized recently, given that gastric pH could affect
DAA bioavailability due to increased or decreased pharmacokinetics, as reported for 3D and
SOF/LDV and in other DAA regimens containing NS3/4A protease inhibitors, such as grazo-
previr, and the NS5A inhibitor elbasvir [23–26]. However, the finding of a post-hoc analysis
provides reassurance that the co-administration of 3D and PPI does not negatively affect the
chance of viral eradication [27].
In conclusion, hundreds of thousands of patients are currently being treated with DAAs,
and, based on our real-life data, 30–44% of those taking comedications are at risk of a DDI.
For several drugs, the recommendation related to a potential DDI depends on the severity of
liver disease, and a careful evaluation of DDIs is required, particularly in patients with severe
Real-life data on potential DDI during DAA therapy
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liver impairment. This stresses the need for increased awareness of this issue and for additional
extensive research.
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